Wanbury Limited

Equities

524212

INE107F01022

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:54 28/06/2024 pm IST 5-day change 1st Jan Change
155.7 INR +0.19% Intraday chart for Wanbury Limited -5.15% +17.95%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Wanbury Gets INR600 Million Term Loan from Tata Capital MT
Wanbury Limited Receives Term Loan Facilities from Tata Capital Limited CI
US FDA Clears Wanbury's Patalganga, India Site; Shares Climb 4% MT
Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director CI
Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Wanbury Limited Approves Appointment of Pravin Dilip Pawar as the Non-Executive Independent Director CI
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Wanbury Limited announced that it expects to receive INR 60 million in funding from Expert Chemicals Pvt. Ltd. CI
Wanbury Limited Appoints Mohan Kumar Rayana as Whole Time Director CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Wanbury Limited Approves Issue of Unlisted, Secured Redeemable, Non-Convertible Debentures CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Wanbury Limited Announces Board Changes CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Wanbury Widens Loss in Fiscal Q2 MT
Wanbury Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Wanbury Limited Auditor Raises 'Going Concern' Doubt CI
Wanbury Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Wanbury Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Wanbury Limited Approves Appointment of Non-Executive Independent Directors CI
Wanbury Limited Approves Board Appointments CI
Wanbury Limited announced that it expects to receive INR 143.0625 million in funding from Expert Chemicals Pvt. Ltd. CI
Wanbury Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Wanbury Limited Announces the Demise of S. K. Bhattacharyya, from the Board of Directors and Committees CI
Chart Wanbury Limited
More charts
Wanbury Limited is an India-based pharmaceutical company having a presence in active pharmaceutical ingredients (APIs) global market and domestic branded formulations. It is engaged in the business of pharmaceutical and related activities, including research. Its API products include metformin, metformin dc, tramadol, sertraline, diphenhydramine hcl, diphenhydramine citrate, mefenamic acid, paroxetine hemihydrate, promethazine, glucosamine, clopidogrel, levetiracetam and carvedilol phosphate monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on development of products like ketamine, rivaroxaban, montelukast, sitagliptin and few others to reduce dependency on metformin and sertraline. The Company has USFDA and EUGMP approved facilities at Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
More about the company
  1. Stock Market
  2. Equities
  3. 524212 Stock
  4. News Wanbury Limited
  5. Wanbury Gets INR600 Million Term Loan from Tata Capital